

Annexin V Binding Buffer

Catalog# / Size	422201 / 100 mL
Regulatory Status	RUO
Other Names	Annexin-V-Binding Buffer
Description	Annexin V Binding Buffer has been formulated for flow cytometric labeling of apoptotic cells with Annexin V reagents. The buffer is provided as a ready-to-use solution.

Product Details

Storage & Handling	Store between 2°C and 8°C.
Application	FC - Quality tested
Recommended Usage	Annexin V Binding Buffer is recommended for use with Annexin V reagents. Cells should be resuspended in Annexin V Binding Buffer at a concentration 1x10 ⁶ /ml and then combined with Annexin V reagents at the recommended volumes.
Application Notes	<p>Annexin V Staining</p> <ol style="list-style-type: none"> 1. Wash cells twice with cold BioLegend cell staining buffer (cat # 420201) and then resuspend cells in Annexin V Binding Buffer (cat # 422201) at a concentration of 1x10⁶ cells/ml. 2. Transfer 100 µl of cell suspension in 5 ml test tube. 3. Add 5 µl of fluorochrome conjugated Annexin V. 4. Add 10 µl of PI solution (cat # 421301) or 7-AAD (cat # 420403/420404). 5. Gently vortex the cells and incubate for 15 min at RT (25 °C) in the dark. 6. Add 400 µl of Annexin V Binding Buffer (cat # 422201) to each tube. Analyze by flow cytometry. <p>For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.</p>

Application References

(PubMed link indicates BioLegend citation)

1. Vermes I, et al. 1995. *J. Immunol. Methods* 184:39.
2. Soon PS, et al. 2013. *Endocr Relat Cancer*. 20:1. [PubMed](#)
3. Turner JE, et al. 2013. *J Exp Med*. [PubMed](#)
4. Lindner JM, et al. 2013. *Mol Cell Biol*. 33:4628. [PubMed](#)
5. Turner JE, et al. 2013 *J. Exp Med*. 210:2951. [PubMed](#)
6. Beggs KM, et al. 2014. *Toxicol Sci*. 137:91. [PubMed](#)
7. Miyazawa M, et al. 2014. *Mol Biol Cell*. 25:2116. [PubMed](#)
8. Burbulla LF, et al. 2014. *Cell Death Dis*. 5:1180. [PubMed](#)
9. de Vires M, 2014. *Am J Physiol Lung Cell Mol Physiol*. 307:240. [PubMed](#)
10. Sahin E, 2014. *J. Immunol*. 193:1717. [PubMed](#)
11. Xiong R, et al. 2014. *Toxicol Appl Pharmacol*. 280:285. [PubMed](#)
12. Thakran S, 2015. *Invest Ophthalmol Vis Sci*. 56:177. [PubMed](#)

Product Citations

1. Tsuji M 2014. *Mol Biol Cell*. 25:2116. [PubMed](#)
2. Guo H, et al. 2016. *Sci Rep*. 6:37559. [PubMed](#)
3. Kitazawa M, et al. 2017. *PLoS One*. 10.1371/journal.pone.0169340. [PubMed](#)
4. Liu M, et al. 2021. *Mol Med Rep*. 23:00. [PubMed](#)
5. Ocklenburg T, et al. 2021. *Sci Rep*. 7199:11. [PubMed](#)
6. Shrestha C, et al. 2017. *PLoS One*. 10.1371/journal.pone.0186169. [PubMed](#)
7. Djeungoue–Petga MA, et al. 2019. *Cell Death Dis*. 1.069444444. [PubMed](#)
8. Forika G, et al. 2021. *Pathol Oncol Res*. 27:1610048. [PubMed](#)
9. Lindner J, et al. 2013. *Mol Cell Biol*. 33:4628. [PubMed](#)
10. Turner J, et al. 2013. *J Exp Med*. 210:2951. [PubMed](#)
11. Itkin T, et al. 2016. *Nature*. 532: 323-328. [PubMed](#)
12. Hergott C, et al. 2016. *Blood*. 127: 2460 - 2471. [PubMed](#)
13. Wang J, et al. 2021. *ACS Nano*. 15:14360. [PubMed](#)
14. Svoronos AA, et al. 2021. *iScience*. 24:103208. [PubMed](#)
15. Wang Q, et al. 2022. *Nat Commun*. 13:3022. [PubMed](#)
16. Olelewe C, et al. 2022. *iScience*. 25:104340. [PubMed](#)
17. Lim JA, et al. 2018. *BMC Cancer*. 0.860416667. [PubMed](#)

18. Venter C, *et al.* 2017. Cell Physiol Biochem. 43:1288. [PubMed](#)
19. Terashima S, *et al.* 2017. J Radiat Res. 10.1093/jrr/rrx025. [PubMed](#)
20. Kim Y, *et al.* 2020. J Neurochem. 155:177. [PubMed](#)
21. Liu Y, *et al.* 2022. Cancer Discov. .: [PubMed](#)
22. Wang M, *et al.* 2022. Immun Inflamm Dis. 10:e626. [PubMed](#)
23. McNeal AS, *et al.* 2021. Elife. 10.: [PubMed](#)
24. Soprano M, *et al.* 2016. PLoS One. 11: 0155970. [PubMed](#)
25. Li L, *et al.* 2016. Cell Death Dis. 7:e2439. [PubMed](#)
26. Moose DL, *et al.* 2020. Cell Rep. 30:3864. [PubMed](#)
27. Wurzer H, *et al.* 2021. Front Immunol. 12:619069. [PubMed](#)
28. Figueroa-Valdés AI, *et al.* 2021. Front Bioeng Biotechnol. 9:619930. [PubMed](#)
29. Yoshioka H, *et al.* 2021. Front Cell Dev Biol. 9:621045. [PubMed](#)
30. Dregalla RC, *et al.* 2021. Stem Cell Res Ther. 12:547. [PubMed](#)
31. Sun V, *et al.* 2021. Front Immunol. 12:716661. [PubMed](#)
32. Herman KD, *et al.* 2022. Front Immunol. 13:956991. [PubMed](#)
33. Coray M, *et al.* 2022. Int J Mol Sci. 23.: [PubMed](#)
34. Vries M, *et al.* 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. [PubMed](#)
35. Naaman H, *et al.* 2017. PLoS One. 10.1371/journal.pone.0187077. [PubMed](#)
36. Elakad O, *et al.* 2022. NPJ Precis Oncol. 6:52. [PubMed](#)
37. Deng J, *et al.* 2021. Cell Death Dis. 12:978. [PubMed](#)
38. Tian AL, *et al.* 2021. Cell Death Dis. 12:6. [PubMed](#)
39. Hickman O, *et al.* 2016. Br J Cancer. 10.1038/bjc.2016.91. [PubMed](#)
40. Hagan AS, *et al.* 2020. Development. 147:00:00. [PubMed](#)
41. Feng S, *et al.* 2017. Cancer Sci. 108:12:00. [PubMed](#)
42. Zhou L, *et al.* 2017. Tumour Biol. 39:1010428317694313. [PubMed](#)
43. Kinsella S, *et al.* 2021. Cell Rep. 37:109789. [PubMed](#)
44. Wilson AS, *et al.* 2022. Nat Commun. 13:528. [PubMed](#)
45. Zhang S, *et al.* 2020. Front Immunol. 1.757638889. [PubMed](#)
46. Li P, *et al.* 2016. Mol Biol Cell. 27: 2542 - 2553. [PubMed](#)
47. Luca E, *et al.* 2020. Mol Metab. 36:100967. [PubMed](#)
48. Saint Fleur-Lominy S, *et al.* 2018. Cell Rep. 24:3045. [PubMed](#)
49. Krishnasamy K, *et al.* 2017. Nat Commun. . 10.1038/s41467-017-00953-2. [PubMed](#)
50. Yang L, *et al.* 2021. Cell Death Differ. 28:2616. [PubMed](#)
51. Wu J, *et al.* 2020. Immunity. 53:115. [PubMed](#)
52. Burbulla L, *et al.* 2014. Cell Death Dis. 5:1180. [PubMed](#)
53. Peiris T, *et al.* 2016. Development. 143: 1697 - 1709.. [PubMed](#)
54. Herold N, *et al.* 2017. Nat Med. 23:256-263. [PubMed](#)
55. Domenis R, *et al.* 2017. PLoS One. 10.1371/journal.pone.0169932. [PubMed](#)
56. Xie S, *et al.* 2021. Sci Rep. 0.660416667. [PubMed](#)
57. Hönes J, *et al.* 2017. Sci Rep. . 10.1038/s41598-017-15866-9. [PubMed](#)
58. Wang P, *et al.* 2019. Nat Commun. 0.940972222. [PubMed](#)
59. Celus W, *et al.* 2021. Cancer Immunol Res. Online ahead of print. [PubMed](#)
60. Cheng CC, *et al.* 2020. Elife. 9:00. [PubMed](#)
61. Leiendecker L, *et al.* 2020. EMBO Mol Med. 12:e12525. [PubMed](#)
62. Jung E, *et al.* 2017. J Neurosci. 37:6837. [PubMed](#)
63. Matsuda K, *et al.* 2021. Cell Rep Methods. 1:100122. [PubMed](#)
64. Carosi JM, *et al.* 2021. Autophagy. 17:2217. [PubMed](#)
65. Li Y, *et al.* 2021. Sci Transl Med. 13.: [PubMed](#)
66. Thakran S, *et al.* 2015. Invest Ophthalmol Vis Sci . 56:177. [PubMed](#)
67. Suarez S, *et al.* 2015. J Biol Chem. 290: 28311 - 28320. [PubMed](#)
68. Deventhiran J, *et al.* 2016. J Virol. 90: 222 - 231. [PubMed](#)
69. Verma N, *et al.* 2020. Sci Adv. 6:00. [PubMed](#)
70. Litzemberger UM, *et al.* 2017. Genome Biol. 18:15. [PubMed](#)
71. Pediconi F, *et al.* 2022. Sci Signal. 15:eabl7989. [PubMed](#)
72. Li C, *et al.* 2021. Cell Metabolism. 33(8):1610-1623.e5. [PubMed](#)
73. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. [PubMed](#)
74. Becker A, *et al.* 2016. Sci Rep. 6: 33847. [PubMed](#)
75. Hopkins T, *et al.* 2015. Nucleic Acids Res. 10.1093/nar/gkv1515. [PubMed](#)
76. Bersini S, *et al.* 2020. Life Sci Alliance. 3:e201900623. [PubMed](#)
77. Lasrado N, *et al.* 2022. iScience. 25:103865. [PubMed](#)
78. Yabas M, *et al.* 2016. PLoS One. 11: 0146774. [PubMed](#)
79. Li B, *et al.* 2019. Oncol Rep. 41:608. [PubMed](#)
80. Wang M, *et al.* 2018. Diabetologia. 62:335. [PubMed](#)
81. Textor A, *et al.* 2021. Cancers (Basel). 13.: [PubMed](#)
82. Molinar-Inglis O, *et al.* 2021. Proc Natl Acad Sci U S A. 118.: [PubMed](#)
83. Erdogan M, *et al.* 2022. Chem Biodivers. 19:e202200659. [PubMed](#)
84. Harro CM, *et al.* 2020. J Clin Invest. . [PubMed](#)
85. Cabet E, *et al.* 2015. PLoS One. 10: 0137009. [PubMed](#)
86. Hasselluhn MC, *et al.* 2019. Cell Death Dis. 0.726388889. [PubMed](#)
87. Zhang S, *et al.* 2018. Sci Rep. 8:17066. [PubMed](#)
88. Lee HW, *et al.* 2018. Am J Physiol Renal Physiol. 314:F280. [PubMed](#)
89. Pascual-Pasto G, *et al.* 2022. J Immunother Cancer. 10.: [PubMed](#)
90. Soon P, *et al.* 2013. Endocr Relat Cancer. 20:1. [PubMed](#)
91. Dong G, *et al.* 2020. Haematologica. . [PubMed](#)
92. Abu El Maaty MA, *et al.* 2021. Sci Adv. 7: . [PubMed](#)
93. Bahl S, *et al.* 2021. Cell Death Dis. 12:469. [PubMed](#)
94. Labi V, *et al.* 2019. Genes Dev. 33:1673. [PubMed](#)
95. Sun T, *et al.* 2019. Cancer Med. 2.457638889. [PubMed](#)
96. Kiss M, *et al.* 2020. Cancer Immunol Res. 9:309. [PubMed](#)
97. Su PL, *et al.* 2021. Lung Cancer. 158:137. [PubMed](#)

98. Beggs K, *et al.* 2014. *Toxicol Sci.* 137:91. [PubMed](#)
99. Guentsch A, *et al.* 2017. *Mol Cell Biol.* 37: e00236-16. [PubMed](#)
100. Festag J, *et al.* 2020. *Mol Ther Nucleic Acids.* 1.330555556. [PubMed](#)
101. Marton N, *et al.* 2017. *Cellular and Molecular Life Sciences.* 10.1007/s00018-017-2535-8. [PubMed](#)
102. Kranz P, *et al.* 2017. *Cell Death Dis.* 8:e2986. [PubMed](#)
103. Wu J, *et al.* 2021. *Adv Sci (Weinh).* 8:e2101029. [PubMed](#)
104. Kojima N, *et al.* 2015. *Anticancer Res.* 35: 4493-4499. [PubMed](#)
105. Xiong R, *et al.* 2014. *Toxicol Appl Pharmacol.* 280:285. [PubMed](#)
106. Pedro L, *et al.* 2019. *Small.* 15:e1900224. [PubMed](#)
107. Rosenberger L, *et al.* 2019. *Sci Rep.* 0.835416667. [PubMed](#)
108. Bensberg M, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:. [PubMed](#)
109. Sahin E, *et al.* 2014. *J Immunol.* 193:1717. [PubMed](#)
110. Kim J, *et al.* 2019. *PLoS One.* 14:e0210248. [PubMed](#)
111. Quan M, *et al.* 2019. *Oncol Rep.* 41:3051. [PubMed](#)
112. Di Franco S, *et al.* 2021. *STAR Protoc.* 2:100880. [PubMed](#)
113. Jatho A, *et al.* 2022. *Cells.* 11:. [PubMed](#)
114. Langsch S, *et al.* 2016. *Cancer Res.* 76: 4160 - 4169. [PubMed](#)
115. Xiong R, *et al.* 2015. *Mol Pharmacol.* 88: 1045 - 1054. [PubMed](#)
116. Vancsik T, *et al.* 2019. *Cancer Med.* 3.313888889. [PubMed](#)
117. Vulin M, *et al.* 2022. *Oncogene.* .: [PubMed](#)
118. Guo P, *et al.* 2022. *Nat Cell Biol.* 24:99. [PubMed](#)

Antigen Details

Gene ID NA

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587